SBP瀬戸内乳腺事業包括的支援機構

最新情報

最新情報

    最新の論文を要約し、コメントをつけて掲載しています。
    是非ダウンロードしてご覧ください。
最新資料DL

ファイル名をクリックしてダウンロードして下さい。

タイトル ファイル名 日付 備考
005:Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer saishin_005.docx 25/03/28 22kb
saishin_005.pdf 651kb
004:Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer saishin_004.docx 25/01/29 21kb
saishin_004.pdf 635kb
003:Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval saishin_003.docx 24/11/29 20kb
saishin_003.pdf 431kb
002:Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Recept or 2–Negative Advanced Breast Cancer saishin_002.docx 24/09/25 23kb
saishin_002.pdf 795kb
001:Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases-1 saishin_001.docx 24/07/19 815kb
saishin_001.pdf 162kb

基礎・疫学

ファイル名をクリックしてダウンロードして下さい。

タイトル ファイル名 日付 備考
基礎・疫学024:A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer kiso_ekigaku_024.pdf 23/11/21 162kb
基礎・疫学023:Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer kiso_ekigaku_023.pdf 23/02/06 120kb
kiso_ekigaku_023_y.pdf
(論文要約)
397kb
基礎・疫学022:High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. kiso_ekigaku_022.docx 22/10/12 23.3KB
基礎・疫学021:Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. kiso_ekigaku_021.docx 22/07/21 30.0kb
基礎・疫学020:Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy. kiso_ekigaku_020.docx 21/12/02 20.0kb
基礎・疫学019:Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. kiso_ekigaku_019.docx 21/08/09 28.3kb
基礎・疫学018:Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. kiso_ekigaku_018.docx 20/09/07 33.3kb
基礎・疫学017:Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. kiso_ekigaku_017.docx 20/04/21 96.0kb
基礎・疫学016:Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. kiso_ekigaku_016.docx 19/12/24 30.4kb
基礎・疫学015:HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. kiso_ekigaku_015.docx 19/07/22 20.2kb
基礎・疫学014:Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer. kiso_ekigaku_014.docx 19/05/13 24.5kb
基礎・疫学013:CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. kiso_ekigaku_013.docx 18/12/05 43.5kb
基礎・疫学012:Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy : Meta-analysis. kiso_ekigaku_012.docx 18/10/05 18.3kb
基礎・疫学011:Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. kiso_ekigaku_011.docx 18/05/16 31.5kb
基礎・疫学010:Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cellsr kiso_ekigaku_010.docx 17/12/12 45.4kb
kiso_ekigaku_010.pdf 768kb
基礎・疫学009:Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer. kiso_ekigaku_009.docx 17/03/27 26.1kb
基礎・疫学008:The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. kiso_ekigaku_008.docx 16/08/16 19.8kb
基礎・疫学007:Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011 kiso_ekigaku_007.docx 16/02/01 17.1kb
基礎・疫学006:Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. kiso_ekigaku_006.docx 15/06/05 24.4kb
基礎・疫学005:PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. kiso_ekigaku_005.docx 14/12/25 16.3kb
基礎・疫学004:Activating ESR1 mutations in hormone-resistant metastatic breast cancer. kiso_ekigaku_004.docx 14/05/16 53.7kb
基礎・疫学003:Factors predicting late recurrence for estrogen receptor-positive breast cancer. kiso_ekigaku_003.docx 14/01/15 19.8kb
基礎・疫学002:Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. kiso_ekigaku_002.doc 13/07/17 34.5kb
基礎・疫学001:Sequence analysis of mutations and translocations across breast cancer subtypes. kiso_ekigaku_001.docx 12/10/18 18.5kb

臨床試験

ファイル名をクリックしてダウンロードして下さい。

タイトル ファイル名 日付 備考
臨床試験034:Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy : a multicentre, single-arm, phase 2 trial. rinsyoushiken_034.pdf 23/04/10 11.5BMB
rinsyoushiken_034-1.pdf
(論文要約)
135.0KB
臨床試験033:Genomics to select treatment for patients with metastatic breast cancer. rinsyoushiken_033.docx 22/12/13 19.0KB
rinsyoushiken_033-1.pdf 4.84MB
臨床試験032:Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. rinsyoushiken_032.docx 22/09/08 28.3KB
臨床試験031:21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.(RxPONDER試験) rinsyoushiken_031.docx 22/03/03 1.41MB
臨床試験030:AI-based pathology predicts origins for cancers of unknown primary. rinsyoushiken_030.pdf 21/10/06 144KB
臨床試験029:Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. rinsyoushiken_029.docx 21/08/26 17.5KB
臨床試験028:Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with earlystage triple-negative breast cancer (IMpassion031):a randomised, double-blind, phase 3 trial. rinsyoushiken_028.docx 21/01/27 17.1KB
臨床試験027:Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. rinsyoushiken_027.docx 20/12/04 38.6KB
臨床試験026:Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS. rinsyoushiken_026.docx 20/11/09 16.0KB
臨床試験025:Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. rinsyoushiken_025.docx 20/08/12 27.5KB
rinsyoushiken_025-1.docx 55.4KB
臨床試験024:The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. rinsyoushiken_024.docx 20/03/04 16.6KB
臨床試験023:Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer rinsyoushiken_023.docx 19/06/10 30.2KB
臨床試験022:Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer rinsyoushiken_022.docx 19/02/14 21.1KB
臨床試験021:Olaparib for Metastatic Breast Cancer  in Patients with a Germline BRCA Mutation rinsyoushiken_021.docx 18/10/05 36.3KB
臨床試験020:Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 rinsyoushiken_020.docx 18/06/06 20.0KB
臨床試験019:20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years rinsyoushiken_019.docx 18/02/21 26.0KB
臨床試験018:Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
(APHINITY試験)
rinsyoushiken_018.docx 17/11/14 26.0KB
臨床試験017:Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype rinsyoushiken_017.docx 17/08/05 37.3KB
臨床試験016:PALOMAstudy rinsyoushiken_016.docx 17/08/05 20.1KB
臨床試験015:MARIANNE試験について rinsyoushiken_015.docx 17/01/16 16.3KB
rinsyou_015edirorial.docx 16.9KB
rinsyou_015negative.docx 12.4KB
臨床試験014:Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer rinsyoushiken_014.docx 16/11/07 16.1KB
臨床試験013:Olanzapine for the Prevention of chemotherapy-Induced Nausea and Vomiting rinsyoushiken_013.docx 16/09/06 18.6KB
臨床試験012:Prospective Validation of a 21-Gene Expression Assay in Breast Cancer rinsyoushiken_012.docx 16/06/15 27.0KB
臨床試験011:Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials rinsyoushiken_011.docx 15/09/24 30.0KB
rinsyou_011_crf_vol2.xls 20/10/09 184.0KB
rinsyou_011_protocol_vol3.docx 177KB
rinsyou_011 plan_vol4.docx 23/06/16 124KB
rinsyou_011 plan_change_vol4.docx 26KB
rinsyou_011_doui_vol4.docx 66KB
rinsyou_011_doui_change_vol4.docx 23KB
hanteitsuchi_20230529.pdf 900KB
臨床試験010:Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer rinsyoushiken_010.docx 15/09/24 26.0KB
臨床試験009:Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy rinsyoushiken_009.docx 15/05/07 20.3KB
臨床試験008:Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer rinsyoushiken_008.docx 15/01/28 52.7KB
臨床試験007:Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA) : a randomised, open-label, phase 3 trial rinsyoushiken_007.docx 14/09/17 18.0KB
臨床試験006:Eff ect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials rinsyoushiken_006.doc 14/07/03 36.0KB
臨床試験005:Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. rinsyoushiken_005.doc 14/02/25 19.5KB
臨床試験004:Trastuzumab Emtansine for HER2-Positive Advanced  Breast Cancer. rinsyoushiken_004.docx 14/01/22 24.6KB
臨床試験003:Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study rinsyoushiken_003.docx 14/01/22 20.1KB
臨床試験002:Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343 rinsyoushiken_002.doc 13/07/17 33.0KB
臨床試験001:Long-term eff ects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial rinsyoushiken_001.docx 13/02/11 20.4KB

検診

ファイル名をクリックしてダウンロードして下さい。

タイトル ファイル名 日付 備考
日本乳癌検診学会最新情報・感想記 nyugankenshin201612.docx 16/12/12 16KB
検診001:Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomized controlled trial kenshin_001.docx 15/12/22 34KB

SBP

瀬戸内乳腺事業包括的支援事業

Copyright (c) SBP. All Right Reserved.